Antisense oligonucleotides: from design to therapeutic application (Q36478849)

14 August 2017

1 reference

title

Antisense oligonucleotides: from design to therapeutic application (English)

1 reference

14 August 2017

Jasmine H P Chan

1

1 reference

14 August 2017

Shuhui Lim

series ordinal

2

1 reference

14 August 2017

W S Fred Wong

series ordinal

3

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Clinical and Experimental Pharmacology and Physiology

14 August 2017

published in

1 reference

14 August 2017

volume

33

1 reference

14 August 2017

issue

5-6

1 reference

14 August 2017

page(s)

533-540

1 reference

Progress in antisense technology.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Antisense technologies. Improvement through novel chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Selecting optimal antisense reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Antisense DNAs as multisite genomic modulators identified by DNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Effects of RNA secondary structure on cellular antisense activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Secondary structure prediction of interacting RNA molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Mfold web server for nucleic acid folding and hybridization prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Automatic extraction of mutations from Medline and cross-validation with OMIM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Predicting oligonucleotide affinity to nucleic acid targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Thermodynamic criteria for high hit rate antisense oligonucleotide design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Prediction of VEGF mRNA antisense oligodeoxynucleotides by RNA structure software and their effects on HL60 and K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Computational antisense oligo prediction with a neural network model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Progress in antisense technology: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Antisense therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Cellular delivery of peptide nucleic acid (PNA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Design of antisense oligonucleotides stabilized by locked nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

LNA: a versatile tool for therapeutics and genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Innovations in oligonucleotide drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

"Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

The use of cell-penetrating peptides as a tool for gene regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Toxicology of antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

Intracellular Uptake and Inhibition of Gene Expression by PNAs and PNA−Peptide Conjugates†

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

On the in vitro and in vivo Properties of Four Locked Nucleic Acid Nucleotides Incorporated into an Anti-H-Ras Antisense Oligonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04403.X

10.1111/J.1440-1681.2006.04403.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference